This site is intended for healthcare professionals

Olumiant improved pain, physical function and morning joint stiffness in rheumatoid arthritis in phase III post-hoc analyses. Eli Lilly

Read time: 1 mins
Last updated:28th Jun 2021
Published:3rd Jun 2021
Lilly and Company and Incyte will present data from post-hoc analyses that suggested Olumiant(baricitinib) 4 mg tablet reduced pain and duration of morning joint stiffness, and improved overall physical function at 12 weeks, among patients with moderate to severe rheumatoid arthritis (RA), compared to Humira (adalimumab) and placebo.
Condition: Rheumatoid Arthritis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest